Emergent BioSolutions to Lead a United States Delegation to the United States - India Business Council (a Subsidiary of the US Chamber of Commerce) Health Summit in India

November 12, 2007

Summit Will Focus on Improving the Quality of Healthcare in India

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 12, 2007--Emergent BioSolutions, Inc. (NYSE:EBS) announced today that the company is leading a delegation to the United States - India Business Council's (USIBC) Healthy India Summit. Dr. Thomas Zink, the Chief Medical Officer and Senior Vice President for Clinical, Medical, and Regulatory Affairs of Emergent BioSolutions, and Dr. Lallan Giri, Vice-President, Science and Business Relations of Emergent BioSolutions, are leading the delegation on behalf of the company. The summit is taking place in New Delhi, India, today, November 12th through November 15th.

The Coalition for Healthy India is committed to improving healthcare outcomes for Indian patients by enabling affordable access to the latest and best treatments and cures. The theme of the conference is "Raising the Standard of Care for Indian Patients" and will focus on a dialogue among leaders and experts in the medical, scientific, and business industries aimed at promoting awareness and developing solutions to address the critical need for healthcare improvements in India.

"Emergent BioSolutions' mission is to protect life and our company is honored to lead this important delegation to the 4th India Health Summit on Healthcare Engagement Strategies and Partnerships which is focused on not only protecting but improving life," stated Dr. Thomas Zink, Chief Medical Officer and Senior Vice President for Clinical, Medical and Regulatory Affairs, Emergent BioSolutions. "We are grateful to the United States - India Business Council for their partnership and look forward to joining experts and industry peers from around the world, who share our commitment to improving the quality of life in India."

Emergent BioSolutions' product portfolio includes a drinkable Typhoid vaccine candidate, a Hepatitis B therapeutic vaccine candidate, Group B streptococcus vaccine candidate, a Chlamydia vaccine candidate, among others. The company announced last month that preliminary results from a Phase II clinical study demonstrated that its single-dose, drinkable typhoid vaccine candidate achieved the study endpoints for safety and immunogenicity. Typhoid is particularly prevalent in India.

The USIBC, a subsidiary of the United States Chamber of Commerce, is the premier business advocacy organization representing America's top companies investing in India, joined by global Indian companies promoting economic reforms with an aim to deepen trade and strengthen commercial ties. The USIBC was formed in 1975 at the request of both the governments of the United States and India, to enhance investment flows between the two countries, and serve as a direct link between business and government leaders. The Council's primary mission is to increase trade and investment between India and the United States.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.

Safe Harbor Statement

CONTACT: Emergent BioSolutions, Inc.
Investors:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or

Media:
Tracey Schmitt
Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com

SOURCE: Emergent BioSolutions, Inc.